Passa al contenuto
Merck
Tutte le immagini(1)

Documenti

SML0141

Sigma-Aldrich

Trilostane

≥98% (HPLC)

Sinonimo/i:

(4α,5α,17β)-3,17-dihydroxy-4,5-epoxyandrost-2-ene-2-carbonitrile

Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali
Tutte le immagini(1)

About This Item

Formula empirica (notazione di Hill):
C20H27NO3
Numero CAS:
13647-35-3
Peso molecolare:
329.43
Numero CE:
237-133-0
Numero MDL:
MFCD00199295
Codice UNSPSC:
51111800
ID PubChem:
329825189
NACRES:
NA.77

Saggio

≥98% (HPLC)

Forma fisica

powder

Colore

white to tan

Solubilità

DMSO: ≥17 mg/mL

Temperatura di conservazione

2-8°C

Stringa SMILE

C[C@]12CC[C@H]3[C@@H](CC[C@@]45O[C@@H]4C(O)=C(C[C@]35C)C#N)[C@@H]1CC[C@@H]2O

InChI

1S/C20H27NO3/c1-18-7-6-14-12(13(18)3-4-15(18)22)5-8-20-17(24-20)16(23)11(10-21)9-19(14,20)2/h12-15,17,22-23H,3-9H2,1-2H3/t12-,13-,14-,15-,17+,18-,19+,20+/m0/s1
KVJXBPDAXMEYOA-CXANFOAXSA-N

Informazioni sul gene

human ... HSD3B2(3284)

Descrizione generale

Trilostane inhibits the production of adrenal steroids, such as cortisol and aldosterone. It is used to treat aldosteronism.

Applicazioni

Trilostane has been used to evaluate its capability to regulate the sex-dependent differences in the lipopolysaccharide (LPS)-induced inflammatory responses of astrocytes.
Trilostane was used to inhibit the activity of 3β-hydroxysteroid dehydrogenase in mouse ovary.

Azioni biochim/fisiol

Trilostane is an inhibitor of 3 β-hydroxysteroid dehydrogenase (3-β-HSD or delta 5-delta 4-isomerase), an essential enzyme for the biosynthesis of all classes of hormonal steroids. It has been used in the treatment of Cushing′s syndrome for stopping the production of cortisol, and is currently approved for dogs in the US, but is still a human drug in the UK and other countries. It is being investigated as a possible treatment for both breast cancer and prostate cancer to prevent the synthesis of estrogens and androgens from endogenous precursors. It has also been used to inhibit endogenous production of progesterone in research studies.

Caratteristiche e vantaggi

This compound is featured on the Nuclear Receptors (Steroids) page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.

Pittogrammi

Health hazardExclamation mark
GHS08,GHS07

Avvertenze

Warning

Indicazioni di pericolo

H315,H319,H361

Classi di pericolo

Eye Irrit. 2 - Repr. 2 - Skin Irrit. 2

Codice della classe di stoccaggio

11 - Combustible Solids

Classe di pericolosità dell'acqua (WGK)

WGK 3

Punto d’infiammabilità (°F)

Not applicable

Punto d’infiammabilità (°C)

Not applicable

Certificati d'analisi (COA)

Cerca il Certificati d'analisi (COA) digitando il numero di lotto/batch corrispondente. I numeri di lotto o di batch sono stampati sull'etichetta dei prodotti dopo la parola ‘Lotto’ o ‘Batch’.

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

Nyssa J Reine
Clinical techniques in small animal practice, 22(1), 18-25 (2007-06-05)
Pituitary-dependent hyperadrenocorticism is a common endocrine disorder in dogs in the United States. Once a diagnosis is established, a decision must be made whether or not to pursue treatment, and if so, which medication to use. Historically, mitotane (Lysodren, o,p'-DDD
P M Y Smets et al.
Journal of veterinary internal medicine, 26(3), 565-574 (2012-04-03)
Systemic hypertension and proteinuria are frequent complications in dogs with Cushing's syndrome and do not always resolve after treatment of hypercortisolism. Therefore, dogs with Cushing's syndrome may be at risk for renal dysfunction before and after treatment. To assess renal
Trilostane treatment of 78 dogs with pituitary-dependent hyperadrenocorticism
Neiger R , et al.
The Veterinary Record, 150(26), 799-803 (2002)
Edward C Feldman
Journal of the American Veterinary Medical Association, 238(11), 1441-1451 (2011-06-02)
To evaluate effectiveness and incidence of adverse reactions to twice-daily lower-dose oral administration of trilostane in the treatment of dogs with naturally occurring hyperadrenocorticism (NOH). Clinical trial. 47 dogs with NOH. 47 dogs were treated orally with trilostane (0.21 to
K-D Cho et al.
Journal of veterinary internal medicine, 27(1), 91-98 (2012-11-22)
Trilostane is commonly used to treat pituitary-dependent hyperadrenocorticism (PDH) in dogs. There are differing opinions regarding the dose and frequency of trilostane administration in dogs with PDH. To compare the efficacy of 2 trilostane protocols in the treatment of dogs
Visualizza tutti i documenti correlati

Articoli

nuclear-receptors-steroids

We offers many products related to Nuclear Receptors (Steroids) for your research needs.

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica.